About Pseudouridylate synthase 1 homolog
Pseudouridylate synthase 1 homolog (PUS1) is a protein
from Homo sapiens identified by UniProt accession
Q9Y606, 427 residues long.
MolForge cross-references it against 0 known binders and
112 disease associations.
Target properties
| Protein name | Pseudouridylate synthase 1 homolog |
| UniProt accession | Q9Y606 |
| Gene | PUS1 |
| Organism | Homo sapiens |
| Length | 427 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (112)
Diseases linked to this target (Open Targets).
- Mitochondrial myopathy and sideroblastic anemia · score 0.81
- myopathy, lactic acidosis, and sideroblastic anemia · score 0.59
- mitochondrial disease · score 0.37
- Intellectual disability · score 0.37
- age at menarche · score 0.28
- genetic disorder · score 0.19
- type 2 diabetes mellitus · score 0.18
- drug use measurement · score 0.18
- erythrocyte count · score 0.16
- Red cell distribution width · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y606-F1 | alphafold | PREDICTED | 80.64 | — |
Amino-acid sequence (427 residues)
MGLQLRALLG AFGRWTLRLG PRPSCSPRMA GNAEPPPAGA ACPQDRRSCS GRAGGDRVWE DGEHPAKKLK SGGDEERREK PPKRKIVLLM AYSGKGYHGM QRNVGSSQFK TIEDDLVSAL VRSGCIPENH GEDMRKMSFQ RCARTDKGVS AAGQVVSLKV WLIDDILEKI NSHLPSHIRI LGLKRVTGGF NSKNRCDART YCYLLPTFAF AHKDRDVQDE TYRLSAETLQ QVNRLLACYK GTHNFHNFTS QKGPQDPSAC RYILEMYCEE PFVREGLEFA VIRVKGQSFM MHQIRKMVGL VVAIVKGYAP ESVLERSWGT EKVDVPKAPG LGLVLERVHF EKYNQRFGND GLHEPLDWAQ EEGKVAAFKE EHIYPTIIGT ERDERSMAQW LSTLPIHNFS ATALTAGGTG AKVPSPLEGS EGDGDTD
Explore Pseudouridylate synthase 1 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets